Advertisement
Advertisement
CHRS
Coherus Oncology, Inc. Common Stock
2.09
USDSponsored
-0.14
-6.08%
Feb 05, 15:58 UTC -5
Closed
Pre-Market
2.10
+0.01
+0.48%
CHRS Earnings Reports
Positive Surprise Ratio
CHRS beat 15 of 40 last estimates.
38%
Next Report
Date of Next Report
Mar 09, 2026
Estimate for Q4 25 (Revenue/ EPS)
$14.22M
/-$0.35
Implied change from Q3 25 (Revenue/ EPS)
+22.88%
/+6.06%
Implied change from Q4 24 (Revenue/ EPS)
-73.74%
/+25.00%
Coherus Oncology, Inc. Common Stock earnings per share and revenue
On Nov 06, 2025, CHRS reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.33 USD, resulting in a 0.45% surprise. Revenue reached 11.57 million, compared to an expected 13.68 million, with a -15.43% difference. The market reacted with a -10.07% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of -0.35 USD, with revenue projected to reach 14.22 million USD, implying an increase of 6.06% EPS, and increase of 22.88% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Coherus Oncology, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Coherus Oncology, Inc. Common Stock reported EPS of -$0.33, missing estimates by 0.45%, and revenue of $11.57M, -15.43% below expectations.
How did the market react to Coherus Oncology, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -10.07%, changed from $1.49 before the earnings release to $1.34 the day after.
When is Coherus Oncology, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 09, 2026.
What are the forecasts for Coherus Oncology, Inc. Common Stock's next earnings report?
Based on 7
analysts, Coherus Oncology, Inc. Common Stock is expected to report EPS of -$0.35 and revenue of $14.22M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement